Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
| Class:Id | LiteratureReference:1660566 |
|---|
| _displayName | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer |
|---|
| _timestamp | 2011-10-13 19:44:25 |
|---|
| author | [Person:349407] Cunningham, David
[Person:1660580] Humblet, Y
[Person:1660570] Siena, S
[Person:1660581] Khayat, D
[Person:1660564] Bleiberg, H
[Person:1660572] Santoro, A
[Person:1660576] Bets, D
[Person:1660565] Mueser, M
[Person:1660573] Harstrick, A
[Person:1660574] Verslype, C
[Person:1660578] Chau, I
[Person:1660585] Van Cutsem, E |
|---|
| created | [InstanceEdit:1660569] Orlic-Milacic, Marija, 2011-10-13 |
|---|
| journal | N Engl J Med |
|---|
| pages | 337-45 |
|---|
| pubMedIdentifier | 15269313 |
|---|
| title | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer |
|---|
| volume | 351 |
|---|
| year | 2004 |
|---|
| (literatureReference) | [Reaction:1248677] Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody [Homo sapiens]
[Pathway:5638303] Inhibition of Signaling by Overexpressed EGFR [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer (1660566)
